Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05745714
Title	HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)
Acronym	HEM-iSMART C
Recruitment	Not yet recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Princess Maxima Center for Pediatric Oncology
Indications	acute lymphoblastic leukemia lymphoblastic lymphoma
Therapies	Cyclophosphamide + Cytarabine + Dexamethasone + Ruxolitinib + Venetoclax
Age Groups:	adult \| child
Covered Countries	NLD